Company Announcement
Copenhagen, Denmark; March 29, 2017 – Genmab A/S
(Nasdaq Copenhagen: GEN) announced today that at
a board meeting the board decided to grant 5,042 restricted stock units to the two new board members and to the new member of management of the Company and
8,400 warrants to the new member of management of the
Company.
Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive
one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on
the date of grant of one Genmab A/S share, DKK 1,427.
The restricted stock units will vest on the first banking day of the month following a period of three years
from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock
unit program adopted by the board of directors in accordance with the general guidelines for incentive-based remuneration adopted
by the shareholders at the annual general meeting. Information concerning Genmab’s restricted stock unit program can be found
on
www.genmab.com under Investors > Stock information >
Restricted stock units.
The exercise price for each warrant is DKK 1,427. Each warrant is awarded cost-free and entitles the owner to
subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the
fair value of each warrant can be calculated as DKK 473.44.
The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the
grant date. The new warrants were granted pursuant to the warrant plan adopted by the board on March 28, 2017. Information
concerning Genmab’s warrant schemes can be found on
www.genmab.com under Investors > Stock information >
Warrants.
About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development
of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved
antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra®
(ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development
for additional multiple myeloma indications, other blood cancers, and solid tumors. A subcutaneous formulation of ofatumumab
is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline.
Genmab's technology base consists of validated and proprietary next generation antibody technologies - the
DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector
function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or
co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more
information visit
www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”,
“intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such statements. The important factors that could cause
our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical
development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the
competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified
personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated
entities, changes and developments in technology which may render our products obsolete, and other factors. For a further
discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake
any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in
relation to actual results, unless required by law.
Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab
logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™;
HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra®
is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc.
Company Announcement no. 12
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/ad684e05-7ada-4ff3-b56f-fe575a13a87b
